A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer

Takashi Ueki; Tatsuya Manabe; Shigetaka Inoue; Jun Ienaga; Naoki Yamanaka; Takuya Egami; Mikimasa Ishikawa; Hiroyuki Konomi; Akashi Ikubo; Kinuko Nagayoshi; Masafumi Nakamura; Masao Tanaka

A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer

Takashi Ueki, Tatsuya Manabe, Shigetaka Inoue, Jun Ienaga, Naoki Yamanaka, Takuya Egami, Mikimasa Ishikawa, Hiroyuki Konomi, Akashi Ikubo, Kinuko Nagayoshi, Masafumi Nakamura, Masao Tanaka

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.

PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.

RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).

CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.

Original language	English
Pages (from-to)	741-747
Number of pages	7
Journal	Anticancer research
Volume	36
Issue number	2
Publication status	Published - Feb 1 2016

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{2cdc044d5fcd4ba1913476b08e365edb,

title = "A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer",

abstract = "AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.",

author = "Takashi Ueki and Tatsuya Manabe and Shigetaka Inoue and Jun Ienaga and Naoki Yamanaka and Takuya Egami and Mikimasa Ishikawa and Hiroyuki Konomi and Akashi Ikubo and Kinuko Nagayoshi and Masafumi Nakamura and Masao Tanaka",

year = "2016",

month = feb,

day = "1",

language = "English",

volume = "36",

pages = "741--747",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2",

}

TY - JOUR

T1 - A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer

AU - Ueki, Takashi

AU - Manabe, Tatsuya

AU - Inoue, Shigetaka

AU - Ienaga, Jun

AU - Yamanaka, Naoki

AU - Egami, Takuya

AU - Ishikawa, Mikimasa

AU - Konomi, Hiroyuki

AU - Ikubo, Akashi

AU - Nagayoshi, Kinuko

AU - Nakamura, Masafumi

AU - Tanaka, Masao

PY - 2016/2/1

Y1 - 2016/2/1

N2 - AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.

AB - AIM: This study was planned to evaluate the efficacy and safety of preoperative capecitabine and oxaliplatin (XELOX) without radiation in patients with locally advanced lower rectal cancer.PATIENTS AND METHODS: Patients with clinical stage II/III lower rectal cancer underwent three cycles of XELOX followed by radical surgery. The primary end-point was the R0 resection rate.RESULTS: Thirty-one patients were recruited between February 2012 and August 2014. The completion rate of neoadjuvant chemotherapy was 96.5% among the 29 patients who received it; the remaining two refused chemotherapy and underwent immediate surgery. Grade 3-4 adverse events occurred in nine patients (31%). All 29 patients who received chemotherapy underwent radical resection. The R0 resection rate was 96.5% among these 29 patients. Pathological complete responses were achieved in three patients (10.3%) and downstaging occurred in 13 (44.8%).CONCLUSION: This pilot study found that neoadjuvant XELOX for locally advanced lower rectal cancer is feasible and safe. This neoadjuvant treatment improved resection margin status.

UR - http://www.scopus.com/inward/record.url?scp=84979831187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979831187&partnerID=8YFLogxK

M3 - Article

C2 - 26851033

AN - SCOPUS:84979831187

SN - 0250-7005

VL - 36

SP - 741

EP - 747

JO - Anticancer Research

JF - Anticancer Research

IS - 2

ER -

A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this